Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
−Removed: Our common stock is traded on the NYSE under the symbol “ARDT.” As of February 20, 2025, there were approximately 210 holders of record of our common stock.
+Added: Our common stock is traded on the NYSE under the symbol “ARDT.” As of March 10, 2026, there were approximately 158 holders of record of our common stock.
A substantially greater number of holders of our common stock are street name or beneficial holders, whose shares of record are held by banks, brokers, and other financial institutions.
Purchases of Equity Securities by Issuer
−Removed: During the three months ended December 31, 2024, we made the following purchases of our equity securities that are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
+Added: In November 2025, our Board of Directors authorized a stock repurchase program pursuant to which we may repurchase an aggregate of up to $50.0 million of our common stock through open market purchases, privately negotiated transactions, block trades or other transactions in accordance with applicable securities laws, subject to market conditions and other factors.
+Added: The program has no expiration date.
+Added: At December 31, 2025, there was approximately $46.8 million of stock repurchase authorization remaining under the stock repurchase program.
+Added: All repurchases under the program during the three months ended December 31, 2025, as shown below, were made in the open market.
+Added: During the three months ended December 31, 2025, we made the following purchases of our equity securities that are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 (dollars in millions, except per share amounts):
Number of Shares Purchased (1)
−Removed: per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
−Removed: Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (2)
+Added: per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Maximum Dollar Value That May Yet Be Purchased Under Publicly Announced Plans or Programs
October 1, 2025 - October 31, 2025 7,755 $ 14.06 — $ —
November 1, 2025 - November 30, 2025 225,311 $ 8.97 225,311 $ 48.0
−Removed: 4,389 17.00 — —
December 1, 2025 - December 31, 2025 129,845 $ 9.01 125,701 $ 46.8
362,911 $ 9.09 351,012
−Removed: 5,804 $ 17.02 — —
−Removed: (1) Represents 5,804 shares withheld by us to satisfy the payment of tax obligations related to the vesting of restricted stock unit awards.
−Removed: (2) We had no publicly announced plans or open market repurchase programs for shares of our common stock during the three months ended December 31, 2024.
+Added: (1) Includes 11,899 shares withheld by us to satisfy the payment of tax obligations related to the vesting of restricted stock unit awards.
Dividend Policy
6 unchanged sentences
The comparisons in the graph below are based on historical data and are not indicative of, nor intended to forecast, future performance of our common stock.
−Removed: COMPARISON OF FIVE-MONTH CUMULATIVE TOTAL RETURN
−Removed: Among Ardent Health Partners, Inc., the S&P 500 Index and the S&P Health Care Index
−Removed: July 18, 2024 July 31, 2024 August 31, 2024 September 30, 2024 October 31, 2024 November 30, 2024 December 31, 2024
−Removed: Ardent Health Partners, Inc.
+Added: COMPARISON OF 17 MONTH CUMULATIVE TOTAL RETURN
+Added: Among Ardent Health, Inc., the S&P 500 Index and the S&P Health Care Index
+Added: July 18, 2024 September 30, 2024 December 31, 2024 March 31, 2025 June 30, 2025 September 30, 2025 December 31, 2025
+Added: Ardent Health, Inc.
$ 100.00 $ 114.45 $ 106.35 $ 85.62 $ 85.06 $ 82.50 $ 54.98
3 unchanged sentences
The performance graph and related information shall not be deemed “soliciting material,” is not deemed “filed” with the SEC, and is not to be incorporated by reference into any future filing under the Securities Act or Exchange Act.
−Removed: Use of Proceeds from Initial Public Offering of Common Stock
−Removed: On July 17, 2024, our registration statement on Form S-1 (File No.
−Removed: 333-280425) related to the initial public offering (the "IPO") was declared effective by the SEC.
−Removed: Pursuant to such registration statement, we issued and sold 12,000,000 shares of common stock at a public offering price of $16.00 per share on July 19, 2024.
−Removed: We received net proceeds of approximately $181.4 million, after deducting underwriting discounts and commissions of approximately $10.6 million.
−Removed: On July 30, 2024, in conjunction with the underwriters exercising their option to purchase additional shares, we issued an additional 1,800,000 shares of common stock at the initial public offering price of $16.00 per share for additional net proceeds of approximately $27.2 million, after deducting underwriting discounts and commissions of approximately $1.6 million.
−Removed: None of the expenses associated with the IPO were paid to directors, officers, or persons owning 10% or more of any class of equity securities, or to our affiliates.
−Removed: As of December 31, 2024, all of the net proceeds from our IPO have been used to acquire complementary healthcare facilities, services and technologies, for general corporate purposes and for working capital.
−Removed: There was no material change in the use of such proceeds from that described in the prospectus for our IPO.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.